Author: Web Desk

CAMBRIDGE, MA / ACCESSWIRE / January 29, 2024 / MindMics, Inc., a leader in health technology innovation, is proud to announce the issuance of its latest patent, US11844618B2, titled "System and Method for Cardiovascular Monitoring and Reporting." This patent marks a significant leap in the field of cardiovascular health, offering a novel, non-invasive approach to disease monitoring and management.

The US11844618B2 patent unveils an advanced cardiovascular monitoring system that ingeniously incorporates acoustic sensors from noise-canceling earbuds. By integrating these sensors with sophisticated machine learning and AI algorithms, the system facilitates continuous, non-invasive monitoring of heart functions. The earbud sensors detect essential biosignals, enabling accurate analysis and prediction of blood pressure and other crucial cardiovascular indicators.

Anna Barnacka, Ph.D., CEO of MindMics and a primary inventor, emphasizes the patent’s significance: "This patent is more than an innovation; it’s a commitment to a healthier future. Our vision extends beyond this invention, aiming to develop adaptable algorithms and software solutions for widespread earbud use. This approach will soon provide unparalleled cardiovascular health insights, with the potential to substantially reduce the global burden of cardiovascular diseases."

Addressing Global Health Challenges:

The rise in hypertension and cardiovascular diseases (CVDs), affecting an estimated one billion people globally, underscores the urgent need for accessible monitoring solutions. The US11844618B2 technology offers a revolutionary approach to managing these conditions, enabling early detection and ongoing monitoring, essential for effective disease control.

MindMics’ Infrasonic Hemodynography (IH) technology, central to this patent, has undergone extensive validation against gold-standard medical assessments, including ECG, echocardiogram, and cardiac catheterization, at Scripps Health. The technology’s efficacy is demonstrated in our study on aortic stenosis, featured in the Journal of the American College of Cardiology (JACC): Case Reports. Additional research covering a wide array of cardiovascular diseases, including Mitral Regurgitation, Pulmonary Hypertension, Heart Failure, and Coronary Artery Disease, is reported at clinicaltrials.gov (NCT04636892). Furthermore, our technology’s capability to differentiate between Atrial Fibrillation (AF) and sinus rhythm, with accuracy comparable to gold-standard ECG, is documented in Nature Digital Medicine.

Innovative Technology Explained:

MindMics’ IH technology leverages low-frequency acoustic biosignals detected in the ear canal, using earbud microphones. This non-invasive method offers comprehensive monitoring of cardiovascular parameters, aligning with the rapidly growing earbud market. MindMics aims to capitalize on this growth by providing health metrics as a software solution, making advanced health monitoring widely accessible.

MindMics’ US11844618B2 patent represents a major advancement in cardiovascular monitoring technology. With its growing patent portfolio and robust clinical validation, MindMics stands at the forefront of transforming cardiovascular health monitoring, building accessible, efficient solutions for early detection and management of heart conditions.

For more information, please visit www.mindmics.com or contact MindMics Public Relations at pr@mindmics.com.

—

About MindMics, Inc.

MindMics brings a next-generation health software platform that turns everyday earbuds by repurposing existing microphones for noise cancellation and other embedded sensors to monitor health accurately. Enabled through in-ear TWS earbuds, MindMics introduces a brand new approach, infrasonic hemodynography, that goes beyond the capabilities of traditional PPG wearable light-based technology, to detect biometrics at a sub-heart rate fidelity with clinical accuracy. This capability opens up game-changing opportunities to provide tangential health information to improve consumer experience across exciting markets, including mindfulness, fitness, gaming, employee care, VR metaverse worlds, and more. www.mindmics.com.

SOURCE: MindMics, Inc.

View the original press release on accesswire.com

FORT MILL, SC / ACCESSWIRE / January 29, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products is participating in the AF Symposium conference. The AF Symposium is taking place in Boston, Massachusetts from February 1-3, at the Omni Seaport Hotel. The AF Symposium was initiated in 1995 in response to the growing epidemic of atrial fibrillation. Over the past 29 years, the meeting has become a major scientific forum at which healthcare professionals have a unique opportunity to learn about advances in research and therapeutics directly from many of the most eminent investigators in the field. The Electrophysiology product divisions from other large companies will be attending including Medtronic (MDT), Boston Scientific (BSX), Abbott (ABT), and Johnson and Johnson (JNJ).

David Jenkins,CEO of Catheter Precision, said, "Participation in medical device conferences enables us to showcase our products to a dedicated audience of physicians. A conference like AF Symposium is unique in that it is dedicated to electrophysiologists. So, while it may be a smaller gathering it is also a very targeted audience and enables us to show our VIVO mapping system and LockeT suture retention device and generate leads and create additional interest."

About VIVO

Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, there by streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.

About LockeT

Catheter Precision’s LockeT is a suture retention device intended to assist in hemostasis after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA.

About Catheter Precision

Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. Reincorporated as Ra Medical Systems, Inc. in Delaware in 2018, the Company changed its name to Catheter Precision, Inc. on August 17, 2023.

CONTACTS:

At the Company

David Jenkins 973-691-2000
IR@catheterprecision.com

SOURCE: Catheter Precision, Inc.

View the original press release on accesswire.com

THOMPSON FALLS, MT / ACCESSWIRE / January 29, 2024 / United States Antimony Corporation ("USAC"), (NYSE:UAMY) is pleased to announce the appointment of Jeffrey Fink, age 39, as Vice President and General Manager of BRZ.

Mr. Fink most recently worked at Enviva Biomass as Regional Director of Operations where he was responsible for all aspects of manufacturing operations for three pellet manufacturing mills with approximately 300 employees. His annual budget was over $200 million. Prior to Enviva, Jeff was Vice President of Operations at US Minerals where he led all manufacturing operations at five plants located throughout the U.S. Accomplishments included reducing direct per ton production costs and closing unprofitable businesses. Jeff holds a degree in Mechanical Engineering (Magna Cum Laude) and a Master’s in Business Administration, both from Virginia Tech University. He also holds several relevant industry licenses.

Commenting on Jeffrey Fink’s appointment today, Gary C. Evans, Chairman of the Board, stated, "Management and the Board of Directors at UAMY completed an exhaustive search over the last several months for a new general manager of our Bear River Zeolite mining operation located in Preston, Idaho. We believe this property has significant potential for increased production volumes. We are very pleased to announce today that this mission has been accomplished with the hiring of Jeffrey (Jeff) Fink as our new Vice President and General Manager of BRZ. Jeff started his new job today and will be moving his family to the general area. Based upon his past experience, his energetic enthusiasm, his passion for safety, and profit minded drive for continuous process manufacturing, we are anticipating substantial improvements (including product supply for our customers) at BRZ under his watch." In response to his new position with the Company, Jeffrey Fink said "I am excited to join the US Antimony and Bear River Zeolite team and look forward to making a substantial positive impact. This situation is nearly identical to turnarounds I have previously performed, and that experience should serve me well as I work with the existing team to make big overall improvements at Bear River."

CONTACT INFORMATION: USAC also announces new contact information for Investor Relations.
Email: info@usantimony.com
Phone: 406-606-4117

About USAC:

United States Antimony Corporation and its subsidiaries in the U.S. and Mexico ("US Antimony", "USAC", the "Company", "we", "us", and "our") sell processed antimony, precious metals, and zeolite products in the U.S. and abroad. The Company processes antimony ore in the U.S. and Mexico primarily into antimony oxide, antimony metal, and antimony trisulfide at its facilities in Montana and Mexico. Our antimony oxide is used to form a flame-retardant system for plastics, rubber, fiberglass, textile goods, paints, coatings and paper, as a color fastener in paint, and as a phosphorescent agent in fluorescent light bulbs. Our antimony metal is used in bearings, storage batteries, and ordnance. Our antimony trisulfide is used as a primer in ammunition. In its operations in Idaho, the Company mines and processes zeolite, a group of industrial minerals used in soil amendment and fertilizer, water filtration, sewage treatment, nuclear waste and other environmental cleanup, odor control, gas separation, animal nutrition, and other miscellaneous applications.

Forward-Looking Statements:

Readers should note that, in addition to the historical information contained herein, this press release may contain forward-looking statements within the meaning of, and intended to be covered by, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based upon current expectations and beliefs concerning future developments and their potential effects on the Company including matters related to the Company’s operations, pending contracts and future revenues, financial performance, and profitability, ability to execute on its increased production and installation schedules for planned capital expenditures, and the size of forecasted deposits. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s most recent filings, including Form 10-K and Form 10-Q with the Securities and Exchange Commission.

Forward-looking statements are typically identified by words such as "believe," "expect," "anticipate," "intend," "outlook," "estimate," "forecast," "project," "pro forma" and other similar words and expressions. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made. Because forward-looking statements are subject to assumptions and uncertainties, actual results or future events could differ, possibly materially, from those anticipated in the forward-looking statements and future results could differ materially from historical performance.

Contact:

United States Antimony Corp.
PO Box 643
47 Cox Gulch Rd.
Thompson Falls, Montana 59873-0643
E-Mail: info@usantimony.com
Phone: (406) 606-4117

SOURCE: United States Antimony Corporation

View the original press release on accesswire.com

CivicEye will be a premier sponsor for NDAA’s Annual Summer Summit this year

CHARLOTTE, NC / ACCESSWIRE / January 29, 2024 / CivicEye, an innovative software solutions provider for prosecutors and law enforcement, is announcing its top-tier sponsorship of the 2024 National District Attorneys Association’s (NDAA) Summer Summit. The event equips prosecutors with Continuing Legal Education (CLE) credits and effective strategies for equitable justice and safeguarding victims’ rights.

Dedicated to "The Prosecutor’s Blueprint to Safeguard Victims and Elevate Their Voices through Enhanced Prosecution, Protection, and Prevention Strategies," the 2024 NDAA Summer Summit will focus on actionable strategies, placing victims at the core of every legal process.

For the second consecutive year, CivicEye is sponsoring the conference to support prosecutors with the resources to keep learning, networking and serving their communities. The company’s software, case management and digital evidence systems tailored for prosecutors, is designed to support prosecutors’ administrative needs and, thereby enhance prosecutors’ capability to focus on pursuing justice.

"We admire that NDAA not only believes in the ongoing learning and knowledge-sharing of prosecutors but also provides the resources for such," said Khristian Gutierrez, CEO of CivicEye. "Their commitment to support prosecutors with spaces to connect with one another and learn is one that we are proud to contribute to."

"Amidst staffing shortages and high caseloads, prosecutors persevere in their pursuit of justice," said Joshua South, Head of Operations at CivicEye. "Our team is proud to create technology that can help propel this mission and support prosecutors in their everyday, vital work."

CivicEye made its sponsorship debut at the 2023 NDAA Summer Summit. Collaborating with TNDAGC and Tennessee’s major city District Attorneys, CivicEye has rapidly expanded its support across Tennessee. Additionally, CivicEye serves prosecutors across various other states.

Prosecutors interested in learning more about CivicEye’s solutions can visit the company’s website to learn more.

The National District Attorneys Association (NDAA) remains neutral and non-partisan, emphasizing integrity and independence in collaborations to ensure fair and unbiased representation in partnerships.

##########

About CivicEye

CivicEye delivers critical software for prosecutors and law enforcement that improves case, records and digital evidence management across the entire criminal justice system. The company provides a full spectrum, cloud-based platform designed to reduce friction points within departments and across stakeholders. CivicEye is headquartered in Charlotte, North Carolina, and serves over 130 agencies across the country.

Media Contact:

Adrienne Clarke, adrienne.clarke@civiceye.com

Sales Contact:

Khristian Gutierrez, khristian@civiceye.com

www.civiceye.com

SOURCE: CivicEye

View the original press release on accesswire.com

CABORCA, MEXICO / ACCESSWIRE / January 29, 2024 / Mexus Gold US (OTCQB:MXSG) ("Mexus" or the "Company) is pleased to announce its’ intent to raise $250,000 US, the estimated amount to pay for its currently outstanding but completed audits bringing Mexus back into compliance with the OTCQB exchange, paying for outstanding claim taxes, and general and administration purposes. The raise will be done by a private placement memorandum offering units in Mexus of one common share at $.005 per share US and a warrant for each share purchased, exercisable at $.015 per share of common stock for up to 24 months from issuance. There are no placement fees associated with the raise. The minimum subscription is $5,000.

Mexus plans to engage a recognized US 3^rd party engineering firm to recommend and oversee QA/QC, along with a Certified lab in the Reno area, and report on the results of a to be planned 8 RC drill hole program with 100 meter depth holes resulting in an expected US SK-1300 SEC compliant inferred (or better) resource report in the area previously test mined by Mexus.

Mexus President and CEO Paul Thompson added, "In the past three years Mexus has opened three test pits with a gold average of 1.5 grams AU per ton of approximately 10,000 tons which were heap leached using carbon in pulp recovery at approximately 70% recovery producing $433,000 dollars US in audited gold sales. With the historical information, assays, and the test mining that has been completed we believe we can develop a resource in excess of one million ounces of gold. The Santa Elena is located near the huge Fresnillio Herradura open pit and on strike with that deposit. With the rising price of gold the timing could not be better and we feel the company has never been more undervalued."

Mexus is open to mutually acceptable opportunities with other mining companies.

About Mexus Gold US
Mexus Gold US is an American based mining company with holdings in Mexico. The fully owned Santa Elena mine is located 54km NW of Caborca, Mexico. Mexus also owns rights to the Ures property located 80km N of Hermosillo, Mexico. This property contains 6900 acres and has both gold and copper on the property. Founded in 2009, Mexus Gold US is committed to protecting the environment, mine safety and employing members of the communities in which it operates.
For more information on Mexus Gold US, visit www.mexusgoldus.com.
Mexus Gold US (775) 721-9960. Paul Thompson Sr

Cautionary Statement
Forward looking Statement: Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company’s future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company’s partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.

SOURCE: Mexus Gold US

View the original press release on accesswire.com